Journal Mobile Options
Table of Contents
Vol. 5, No. 3, 2012
Issue release date: September – December
Open Access Gateway
Case Rep Oncol 2012;5:639–643
(DOI:10.1159/000345955)
Published: December 2012

Esophageal Metastasis to the Iris Effectively Palliated Using Stereotactic Body Radiation Therapy and Adjuvant Intravitreal Chemotherapy: Case Report and Literature Review

Dhakal S.a · Lema G.M.C.b · DiLoreto Jr D.A.b · Katz A.W.a
Departments of aRadiation Oncology and bOphthalmology, University of Rochester Medical Center, Rochester, N.Y., USA

Abstract

We report a case of isolated iris metastasis from esophageal adenocarcinoma that was successfully managed with local application of stereotactic body radiation therapy (SBRT) and adjunctive intravitreal therapy. A 53-year-old man with locally advanced esophageal adenocarcinoma achieved a complete clinical and radiographic response after surgery and chemotherapy. Four months later, he developed headache and decreased vision and was diagnosed with metastasis to the iris by slit-lamp examination. The decrease in vision was secondary to cystoid macular edema. The metastatic tumor and the patient’s symptoms resolved after treatment with SBRT and intravitreal injections of bevacizumab and triamcinolone. We conclude that SBRT combined with intravitreal chemotherapy is an effective and well-tolerated palliative treatment for metastasis of esophageal adenocarcinoma to the iris.

 goto top of outline Author Contacts

Sughosh Dhakal, MD
University of Rochester Medical Center
601 Elmwood Ave., Box 647
Rochester, NY 14642 (USA)
E-Mail: sughosh_dhakal@urmc.rochester.edu


 goto top of outline Article Information

Published online: December 6, 2012
Number of Print Pages : 5
Number of Figures : 2,


 goto top of outline Publication Details

Case Reports in Oncology

Vol. 5, No. 3, Year 2012 (Cover Date: September - December)

Journal Editor: Markman M. (Philadelphia, Pa.)
ISSN: 1662-6575 (Print), eISSN: 1662-6575 (Online)

For additional information: http://www.karger.com/CRO


Open Access License / Drug Dosage

Open Access License: This is an Open Access article licensed under the terms of the Creative Commons Attribution-NonCommercial 3.0 Unported license (CC BY-NC) (www.karger.com/OA-license), applicable to the online version of the article only. Distribution permitted for non-commercial purposes only.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.